Piedra, A, Guinart-Cuadra, A, Mulet, M, Zamora, C, Alejandre, J, Martínez-Recio, S, Barba, A, Sullivan, I, Serra-López, J, Isla, D, Arriola, E, Paz-Ares, L, Diz, MP, Moreno, AL, Callejo, A, Vidal, S, Majem, M. Basal Circulating Leukocyte-Platelet Complexes and PD-L1 Expression on Circulating Cells in Patients with Advanced SCLC. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Provencio, M, Nadal, E, Insa, A, Campelo, MRG, Calvo, V, Palmero, R, Lázaro, M, Dómine, M, Majem, M, Rodríguez-Abreu, D, Martínez-Martí, A, Carpeño, JDC, Cobo, M, Bernabé, R, Viñolas, N, Barneto, I, Viteri, S, Cruz-Bermudez, A, Romero, A, Massutí, B. Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-SmallCell Lung Cancer (NADIM Trial). Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Garcia-Campelo, R, Gómez, MD, de Castro, J, Vega, AM, Aix, SP, Arriola, E, Carcereny, E, Majem, M, Vence, GH, González, EE, Pradera, JF, Granados, ALO, Morales, MG, Sureda, BM, Núñez, NF, Provencio, M, González-Mancha, N, Fajardo, CA, Lerones, N, Dols, MC. Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Martínez-Toledo, C, Sierra, B, Molina-Alejandre, M, Casarrubios, M, Calvo, V, Nadal, E, Campelo, MRG, Martínez-Martí, A, Garrido, A, Massutí, B, Insa, A, De Castro, J, Dóomine, M, González-Larriba, JL, Majem, M, Ponce, S, Barneto, I, Aguilar, A, Martín-López, J, Provencio, M, Cruz-Bermúdez, A. TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Spigel, DR, Ahn, MJ, Majem, M, Rodríguez, LM, Lee, KH, Carcereny, E, Hernández, AA, Insa, A, Cho, EK, Besse, B, Rha, SY, Weiss, J, D'Arcangelo, M, Im, SA, Kim, SW, Carneiro, BA, Gadgeel, SM, Mitchell, P, Asare, JM, Gainer, SD, Achour, I, Subramaniam, DS, Felip, E. Volrustomig plus platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Nguyen, D, Besse, B, Cho, BC, Lee, SH, Lee, KH, Lu, S, Cheng, Y, Yao, Y, Girard, N, Lin, CC, Felip, E, Aguilar, A, Charoentum, C, Cruz, FJSM, Majem, M, Lim, CS, Akamatsu, H, Hayashi, H, Yang, JCH, Kowalyszyn, R, Tiscoski, K, Franke, F, Ponomarenko, D, Arslan, C, Forster, M, Urban, D, Misch, D, Delmonte, A, Montes, LVG, Gadgeel, SM, Cruz-Correa, M, Peguero, J, Rousey, S, Gaffar, Y, Owen, S, Schuchard, J, Diels, J, Sermon, J, Sun, T, Ennis, M, Fennema, E, Daksh, M, Sethi, S, Bauml, JM, Campelo, MRG. Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Rodriguez-Vida, A, Valderrama, BP, Castellano, D, Pinto, A, Mellado, B, Puente, J, Climent, MA, Domenech, M, Vazquez, F, Perez-Gracia, JL, Bonfill, T, Morales-Barrera, R, Gonzalez-Billalabeitia, E, Garcia-del-Muro, X, Maroto, P, Navarro-Gorro, N, Juanpere, N, Juan, O, Bellmunt, J. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study. ESMO Open. 2024; 9(9)DOI:10.1016/j.esmoop.2024.103690. PMID:39214051. IF:8.300(Q1/2D).

Tibau, A, Hwang, TJ, Avorn, J, Kesselheim, AS. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study. BMJ-British Medical Journal. 2024; 386DOI:10.1136/bmj-2023-079126. PMID:39164034. IF:42.700(Q1/1D).

Peressini, M, Garcia-Campelo, R, Massuti, B, Marti, C, Cobo, M, Gutiérrez, V, Dómine, M, Fuentes, J, Majem, M, de Castro, J, Córdoba, JF, Diz, MP, Isla, D, Esteban, E, Carcereny, E, Vila, L, Moreno-Vega, A, Ros, S, Moreno, A, García, FJ, Huidobro, G, Aguado, C, Cebey-López, V, Valdivia, J, Palmero, R, Lianes, P, López-Brea, M, Vidal, OJ, Provencio, M, Arriola, E, Baena, J, Herrera, M, Bote, H, Molero, M, Adradas, V, Ponce-Aix, S, Nuñez-Buiza, A, Ucero, A, Hernandez, S, Lopez-Rios, F, Conde, E, Paz-Ares, L, Zugazagoitia, J. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer. CLINICAL CANCER RESEARCH. 2024; 30(14)DOI:10.1158/1078-0432.CCR-24-0104. PMID:38630755. IF:10.200(Q1/1D).

Moreno-Cabrera, JM, Feliubadaló, L, Pineda, M, Prada-Dacasa, P, Ramos-Muntada, M, Del Valle, J, Brunet, J, Gel, B, Currás-Freixes, M, Calsina, B, Salazar-Hidalgo, ME, Rodríguez-Balada, M, Roig, B, Fernández-Castillejo, S, Domínguez, M, Ledo, M, Sanz, MI, Castillejo, A, Dámaso, E, Soto, JL, de Miguel, M, Calero, B, Sánchez-Zapardiel, JM, Ramon, T, Lasa, A, Gisbert-Beamud, A, López-Novo, A, Ruiz-Ponte, C, Potrony, M, Alvarez-Mora, M, Osorio, A, Lorda-Sánchez, I, Robledo, M, Cascon, A, Ruiz, A, Spataro, N, Hernan, I, Borràs, E, Moles-Fernández, A, Earl, J, Cadiñanos, J, Sánchez-Heras, AB, Bigas, A, Capellá, G, Lazaro, C. SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population. Database-The Journal of Biological Databases and Curation. 2024; 2024DOI:10.1093/database/baae055. PMID:38965703. IF:3.600(Q1/1D).

Gregorc, V, González-Cao, M, Salvagni, S, Koumarianou, A, Gil-Bazo, I, Maio, M, Viteri, S, Majem, M, Gutiérrez, V, Caro, RB, Sanmamed, MF, Zhu, HQ, Shen, HG, Wang, Y, Rosell, R. KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(17_SUPPL)DOI:10.1200/JCO.2024.42.17_suppl.LBA8511. PMID:. IF:41.900(Q1/1D).

Tibau, A, Kesselheim, AS. Global cooperation and early access-clinical outcomes matter. LANCET ONCOLOGY. 2024; 25(6)DOI:10.1016/S1470-2045(24)00210-9. PMID:38754452. IF:35.900(Q1/1D).

Gately, L, Mesía, C, Sepúlveda, JM, del Barco, S, Pineda, E, Gironés, R, Fuster, J, Dumas, M, Gill, S, Navarro, LM, Herrero, A, Dowling, A, de las Peñas, R, Vaz, MA, Alonso, M, Lwin, Z, Harrup, R, Peralta, S, Long, A, Perez-Segura, P, Ahern, E, Garate, CO, Wong, M, Campbell, R, Cuff, K, Jennens, R, Gallego, O, Underhill, C, Martinez-Garcia, M, Covela, M, Cooper, A, Brown, S, Rosenthal, M, Torres, J, Collins, IM, Gibbs, P, Balana, C. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM). JOURNAL OF NEURO-ONCOLOGY. 2024; 168(2)DOI:10.1007/s11060-024-04668-5. PMID:38630385. IF:3.100(Q2/4D).

Tibau, A, Hwang, TJ, Avorn, J, Kesselheim, AS. Clinical applicability of guideline-recommended molecular targets and genometargeted cancer therapies. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

Serda, PC, Cullell, BM, Castet, F, Gatell, AP, Fernandez, PR, Fernandez, J, Nadal, TS, Mateo, FJP, Sorolla, MA, Cajal, TRY. Chemotherapy sensitivity in pancreatic neoplasms with PALB2 Gene mutations: First results of PALB2 pancreatic cancer study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/annonc.2024.05.508. PMID:. IF:65.400(Q1/1D).

Reinacher-Schick, AC, Lopez, MR, Alonso-Orduña, V, Lopez-Bravo, DP, Vergauwe, P, Tannapfel, A, Silveira, AB, Schlombs, K, Young, P, He, Y, Henn, H, Manning, L, Preussner, L, Mueller, F, Sahin, U, Türeci, O. Preliminary results correlating post-operative ctDNA status with disease-free survival in patients with stage II (high risk)/III colorectal cancer in the BNT000-001 epidemiology study. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

Schreurs, MAC, Cajal, TRY, Adank, MA, Collée, JM, Hollestelle, A, van Rooij, J, Schmidt, MK, Hooning, MJ. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families (vol 73, 103611, 2024). BREAST. 2024; 75DOI:10.1016/j.breast.2024.103723. PMID:. IF:7.900(Q1/1D).

Aggarwal, C, Martinez-Marti, A, Majem, M, Barlesi, F, Carcereny, E, Chu, QS, Monnet, I, Sanchez, A, Dakhil, SR, Camidge, DR, Pillet, M, Brown, M, Dowson, A, Cooper, ZA, Kumar, R, Herbst, RS. Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

Berciano-Guerrero, MA, Perez-Ruiz, E, Couselo, EM, Manzano, JL, Cerezuela-Fuentes, P, de Miguel, PA, Soria, A, Castaño, AG, Crespo, G, Puértolas, T, De La Rosa, CA, Sanz, LG, Castro, RL, Espinosa, E, Lecumberri, MJ, Majem, M, Martinez, JM, Bellido, L, Fernández-Morales, LA, Martin-Algarra, S. Real-world effectiveness and safety of dabrafenib-trametinib as first-line of treatment for BRAF mutated metastatic melanoma: Results of the study GEM1801. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

Martelli, V, Barrull, JV, Rodriguez, CF, Alfonso, PG, Paez, D, Gibert, J, Alonso, V, España, MAG, Vivas, CS, Ogalla, GD, Fernandez, MEE, Garcia-Carbonero, R, Monteagudo, RF, Mozo, JLM, Losa, F, Paricio, BB, Tabernero, J, Soler, RS, Aguilar, EA, Viladot, CM. Circulating tumor DNA (ctDNA) to detect acquired resistance to first-line (1L) treatment of RASWT metastatic colorectal cancer (mCRC): Insights from the PLATFORM-B study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.121. PMID:. IF:65.400(Q1/1D).